HealthEquity has experienced impressive growth in revenue and EBITDA over the past decade. In the most recent quarter, the company reported a beat on both revenues and EPS as a result of margin ...

While Oracle has outperformed the broader market with a 25.8% gain over the past six months against the Zacks Computer and Technology sector's 4.9% and the S&P 500's 6.4% gain, respectively, this ...

Enterprise value to EBITDA (earnings before interest, taxes depreciation, and amortization) is one of the most commonly used valuation ratios. According to a 2015 paper, almost 80% of equity analysts ...

Despite Five9's FIVN compelling growth story and AI-driven potential, its current valuation metrics suggest investors might want to exercise caution and wait for a better entry point in 2025. The ...

We created a discounted cash flow model ("DCF") to calculate a range of theoretically supportable EV/EBITDA multiples, given analysts' expectations for 2022-2024 and reasonable assumptions for the ...

MAGN reported its inaugural Q1 2025 earnings report, making known many of the unknowns surrounding this spinoff. I reiterate my BUY rating for MAGN, believing there's significant upside potential.